New obesity, diabetic cures may emerge as scientists unveil brain atlasÂ
Scientists have created an atlas of individual cells within the human brain region of the hypothalamus and identified new genes linked to obesity.
Uncategorized
Uncategorized
EU panel gives a positive opinion for AstraZeneca’s cancer drug
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish.
Uncategorized
J&J’s nasal spray to treat major depressive disorder gets FDA nod
The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at.
Uncategorized
One in 127 people globally have autism spectrum disorder: Study
About 61.8 million globally, or one in every 127 people, had autism spectrum disorder in 2021, according to new research that expanded on.
Uncategorized
Novo Nordisk says its drug CargiSema cuts body weight by 22.7% in adults
Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.
Uncategorized
Elevated β-hCG linked to BRCA1 mutations in breast cancer
Bharti Jayshankar December 16, 2024: Researchers at the Rajiv Gandhi Biotechnology Centre, Kerala, delving into the molecular mechanisms of tumorigenesis by BRCA1 gene,.
Uncategorized
Eli Lilly to expand US facility as demand soars for diabetes, obesity medicines
Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for.
Uncategorized
Danaher’s Cepheid gets first WHO prequalification nod for TB tests
Cepheid Inc., a US molecular diagnostics company and a wholly-owned arm of Danaher Corporation has been granted WHO prequalification for its diagnostic tests.
Health
Uncategorized
EU regulators reverse course, approve Alzheimer’s drug Leqembi
HQ Team November 19, 2024: The European Medicines Agency (EMA) granted conditional approval for lecanemab, for the treatment of early Alzheimer’s disease in.
Uncategorized
Climate inaction may cost global economy $190 trillion: Deloitte
Climate inaction may cost the global economy $190 trillion by 2070 due to a decline in agricultural and labour productivity and damage to capital and.